Titre :

Fascin-1 expression is associated with neuroendocrine prostate cancer and directly suppressed by androgen receptor

Auteur(s) :

Turpin, Anthony [Auteur]
Delliaux, Carine [Auteur]
Parent, Pauline [Auteur]
Chevalier, Hortense [Auteur]
Escudero-Iriarte, Carmen [Auteur]
Bonardi, Franck [Auteur]
Vanpouille, Nathalie [Auteur]
Flourens, Anne [Auteur]
Querol, Jessica [Auteur]
Carnot, Aurélien [Auteur]
Leroy, Xavier [Auteur]
Herranz, Nicolás [Auteur]
Lanel, Tristan [Auteur]
Villers, Arnauld [Auteur]
Olivier, Jonathan [Auteur]
Touzet, Hélène [Auteur]
Centre de Recherche en Informatique, Signal et Automatique de Lille - UMR 9189 [CRIStAL]
De Launoit, Yvan [Auteur]
Tian, Tian [Auteur]
Duterque-Coquillaud, Martine [Auteur correspondant]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]

Titre de la revue :

British Journal of Cancer

Éditeur :

Cancer Research UK

Date de publication :

2023-10-24

ISSN :

0007-0920

Mot(s)-clé(s) en anglais :

Prostate - Cancer
neuroendocrine
Androgen receptor
fascin1

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Abstract Background Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer, arising from resistance to androgen-deprivation therapies. However, the molecular mechanisms associated with NEPC development ...
Lire la suite >Abstract Background Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer, arising from resistance to androgen-deprivation therapies. However, the molecular mechanisms associated with NEPC development and invasiveness are still poorly understood. Here we investigated the expression and functional significance of Fascin-1 (FSCN1), a pro-metastasis actin-bundling protein associated with poor prognosis of several cancers, in neuroendocrine differentiation of prostate cancer. Methods Differential expression analyses using Genome Expression Omnibus (GEO) database, clinical samples and cell lines were performed. Androgen or antagonist’s cellular treatments and knockdown experiments were used to detect changes in cell morphology, molecular markers, migration properties and in vivo tumour growth. Chromatin immunoprecipitation-sequencing (ChIP-Seq) data and ChIP assays were analysed to decipher androgen receptor (AR) binding. Results We demonstrated that FSCN1 is upregulated during neuroendocrine differentiation of prostate cancer in vitro, leading to phenotypic changes and NEPC marker expression. In human prostate cancer samples, FSCN1 expression is restricted to NEPC tumours. We showed that the androgen-activated AR downregulates FSCN1 expression and works as a transcriptional repressor to directly suppress FSCN1 expression. AR antagonists alleviate this repression. In addition, FSCN1 silencing further impairs in vivo tumour growth. Conclusion Collectively, our findings identify FSCN1 as an AR-repressed gene. Particularly, it is involved in NEPC aggressiveness. Our results provide the rationale for the future clinical development of FSCN1 inhibitors in NEPC patients.Lire moins >

Langue :

Anglais

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL